Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.3700
Nov 18 • 8:31 AM ET Dollar change+0.0050 Percentage change(1.37%)
Index
-
Market Cap
5.52M
Enterprise Value
-2.06M
Income
-13.78M
Sales
0.00M
Book/sh
0.09
Cash/sh
0.51
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
16
IPO
Jun 11, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
3.92
P/C
0.72
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
1.49
Current Ratio
1.49
Debt/Eq
0.04
LT Debt/Eq
0.01
Option/Short
Yes / Yes
EPS (ttm)
-1.60
EPS next Y
-2.02
EPS next Q
-0.35
EPS this Y
-3.82%
EPS next Y
-23.93%
EPS next 5Y
-10.36%
EPS past 3/5Y
-6.13% -10.59%
Sales past 3/5Y
- -
EPS Y/Y TTM
9.68%
Sales Y/Y TTM
-
EPS Q/Q
3.50%
Sales Q/Q
-
Insider Own
22.23%
Insider Trans
0.00%
Inst Own
27.71%
Inst Trans
0.13%
ROA
-124.41%
ROE
-250.59%
ROIC
-972.15%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-33.90%
SMA50
-58.77%
SMA200
-83.77%
Trades
Shs Outstand
14.94M
Shs Float
11.61M
52W High
4.34 -91.47%
52W Low
0.36 2.21%
Volatility
14.31% 16.19%
ATR (14)
0.10
RSI (14)
24.56
Beta
2.58
Rel Volume
14.04
Avg Volume
245.74K
Volume
172,456
Perf Week
-23.08%
Perf Month
-43.63%
Perf Quarter
-83.84%
Perf Half Y
-88.33%
Perf YTD
-87.79%
Perf Year
-88.47%
Perf 3Y
-90.82%
Perf 5Y
-95.68%
Perf 10Y
-
Prev Close
0.37
Price
0.37
Change %
1.37%
Consensus
Strong Buy
Avg. Price Target
$22.00
Implied Upside
+5,845.9%
Analysts2incl. previous ratings
Rating Distribution1 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
TodayDowngrade
RRodman & Renshaw
Buy → Neutral
Oct 07, 2021Initiated
HH.C. Wainwright
Buy$32+8,548.6%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schalop Lee TroyDirectorMay 12 '26Buy2.0648,544100,00148,544May 14 04:10 PM
KEYSER D JEFFREYDirectorMay 12 '26Buy2.0648,544100,00194,303May 14 04:10 PM
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
PresidentMr. Panna Sharma
CFO & SecretaryMr. David R. Margrave
Chief Scientific Officer & Scientific ConsultantDr. Kishor Gopaldas Bhatia Ph.D.
M.S.Dr. Peter L. Nara D.V.M.
Chief Medical Officer of Starlight TherapeuticsDr. Marc C. Chamberlain M.D.